Evaluation of drug carrier hepatotoxicity using primary cell culture models

Basit Öğe Kaydı
dc.authoridKIBAR, GUNES/0000-0002-2586-6770
dc.authoridDUTTA, SUBHADEEP/0000-0002-1741-7027
dc.contributor.authorKibar, Gunes
dc.contributor.authorDutta, Subhadeep
dc.contributor.authorRege, Kaushal
dc.contributor.authorUsta, O. Berk
dc.date.accessioned2025-01-06T17:43:31Z
dc.date.available2025-01-06T17:43:31Z
dc.date.issued2023
dc.description.abstractThis study aims to establish a primary rat hepatocyte culture model to evaluate dose-dependent hepatotoxic effects of drug carriers (lipopolymer nanoparticles; LPNs) temporal. Primary rat hepatocyte cell cultures were used to determine half-maximal Inhibition Concen-trations (IC50) of the drug-carrier library. Drug-carrier library, at concentrations <50 mu g/mL, is benign to primary rat hepatocytes as determined using albumin and urea secretions. Albumin, as a hepatic biomarker, exhibited a more sensitive and faster outcome, compared to urea, for the determination of the IC50 value of LPNs. Temporal measurements of hepatic biomarkers including urea and albumin, and rigorous physi-cochemical (hydrodynamic diameter, surface charge, etc.) characterization, should be combined to evaluate the hepatotoxicity of drug carrier libraries in screens.(c) 2023 Published by Elsevier Inc.
dc.description.sponsorshipNational Institutes of Health [NIH 1R21GM136002]; NIH [R41 TR003247]; National Science Foundation (NSF Engineering Research Center) [1941543]; Massachusetts General Hospital (MGH) Executive Committee on Research (ECOR); Turkish Fulbright Commission; Fulbright Postdoctoral Scholarship; Scientific and Technological Research Council of Turkey (Tubitak); [1059B191801017]
dc.description.sponsorshipThis research was supported by grants from the National Institutes of Health (NIH 1R21GM136002 and NIH 5R01HL145031) , the National Science Foundation (NSF Engineering Research Center, Award #1941543) , and a Massachusetts General Hospital (MGH) Executive Committee on Research (ECOR) Interim Support Fund at Dr. Usta's lab. We also acknowledge the support and use of facilities at the Morphology and Imaging Shared Facility, and Regenerative Medicine Shared Facility provided at the Shriners'Children-Boston. We also acknowledge the Turkish Fulbright Commission for a Fulbright Postdoctoral Scholarship and the Scientific and Technological Research Council of Turkey (Tubitak 2219 Award #1059B191801017) for Dr. Gunes Kibar. We are also grateful to the NIH (Grant R41 TR003247 to Synergyan, LLC and KR) for partially supporting this study at Dr. Rege's lab. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the NSF.
dc.identifier.doi10.1016/j.nano.2023.102651
dc.identifier.issn1549-9634
dc.identifier.issn1549-9642
dc.identifier.pmid36623713
dc.identifier.scopus2-s2.0-85146439950
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.nano.2023.102651
dc.identifier.urihttps://hdl.handle.net/20.500.14669/2678
dc.identifier.volume48
dc.identifier.wosWOS:000975315200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofNanomedicine-Nanotechnology Biology and Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241211
dc.subjectLipopolymer nanoparticle (LPN)
dc.subjectNanotoxicity
dc.subjectPrimary rat hepatocyte
dc.subjectIn vitro culture
dc.subjectHepatotoxicity
dc.titleEvaluation of drug carrier hepatotoxicity using primary cell culture models
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu